Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition

BACKGROUND: In ALK-positive advanced NSCLC, crizotinib has a high response rate and effectively increases quality of life and survival. CT measurement of the tumor may insufficiently reflect the actual tumor load changes during targeted therapy with crizotinib. We explored whether (18)F-FDG PET meas...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS One
Päätekijät: Kerner, Gerald S. M. A., Koole, Michel J. B., Bongaerts, Alphons H. H., Pruim, Jan, Groen, Harry J. M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2016
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854442/
https://ncbi.nlm.nih.gov/pubmed/27137772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0149955
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia